SEC Comment Letter for Forte Biosciences, Inc. (FBRX) (CIK 0001419041) (FBRX) — Mar 23, 2017
Forte Biosciences, Inc. (FBRX) (CIK 0001419041)
Date: March 23, 2017 · CIK: 0001419041 · Accession: 0000000000-17-009658
AI Filing Summary & Sentiment
Letter
Mailstop 4546 March 23, 2017 Martin J. Duvall Chief Executive Officer Tocagen Inc. 3030 Bunker Hill Street, Suite 230 San Diego, CA 92109
Re: Tocagen Inc. Registration Statement on Form S -1 Filed March 9, 2017 File No. 333 -216574
Dear Mr. Duvall:
We have reviewed your registration statement and have the following comment . Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the in formation you provide in response to our comment , we may have additional comments.
Management Executive Officers, page 133
1. Please revise Mr. Foletta’s background to describe his business experience during the past five years. Please see Item 401(e) of Regulation S -K for guidance.
We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.
Martin J. Duvall Tocagen , Inc. March 23 , 2017 Page 2
You may contact Mary Mast at (202) 551 -3613 or Sharon Blume at (202) 551 -3474 if you have questions regarding comments on the financial statements and related matters. Please contact Johnny Gharib at (202) 551 -3170 or me at (202) 551 -3675 with any other questions.
Sincerely,
/s/ Suzanne Hayes
Show Raw Text
Mailstop 4546 March 23, 2017 Martin J. Duvall Chief Executive Officer Tocagen Inc. 3030 Bunker Hill Street, Suite 230 San Diego, CA 92109 Re: Tocagen Inc. Registration Statement on Form S -1 Filed March 9, 2017 File No. 333 -216574 Dear Mr. Duvall: We have reviewed your registration statement and have the following comment . Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the in formation you provide in response to our comment , we may have additional comments. Management Executive Officers, page 133 1. Please revise Mr. Foletta’s background to describe his business experience during the past five years. Please see Item 401(e) of Regulation S -K for guidance. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Martin J. Duvall Tocagen , Inc. March 23 , 2017 Page 2 You may contact Mary Mast at (202) 551 -3613 or Sharon Blume at (202) 551 -3474 if you have questions regarding comments on the financial statements and related matters. Please contact Johnny Gharib at (202) 551 -3170 or me at (202) 551 -3675 with any other questions. Sincerely, /s/ Suzanne Hayes Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Karen E. Deschaine, Esq. Cooley LLP